Relatlimab and nivolumab in the treatment of melanoma.

Au, Lewis; Larkin, James; Turajlic, Samra

Au, Lewis; Larkin, James; Turajlic, Samra.

Afiliação

Au L; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, VIC 3010, Australia; Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Larkin J; Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK. Electronic address: james.larkin@rmh.nhs.uk.
Turajlic S; Cancer Dynamics Laboratory, The Francis Crick Institute, London NW1 1AT, UK; Renal and Skin Units, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK; Melanoma and Kidney Cancer Team, The Institute of Cancer Research, London SW7 3RP, UK. Electronic address: samra.turajlic@crick.ac.uk.

Cell ; 185(26): 4866-4869, 2022 12 22.

Article em En | MEDLINE | ID: mdl-36563660

Assuntos

Melanoma; Nivolumabe; Humanos; Nivolumabe/uso terapêutico; Ipilimumab; Melanoma/tratamento farmacológico; Melanoma/patologia; Anticorpos Monoclonais Humanizados/uso terapêutico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Pele Base de dados: MEDLINE Assunto principal: Nivolumabe / Melanoma Limite: Humans Idioma: En Revista: Cell Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google